Glycostem's NK Cell Product oNKordĀ® received Orphan drug designation for AML

ODD for NK Cell Product oNKordĀ® to treat AML

NK_Figuren3.jpg

18 November 2014, EMA/COMP/641491/2014

During their plenary meeting on 11-13 November 2014 the Committee for Orphan Medicinal Products (COMP) has adopted at the first discussion a positive opinion recommending Glycostem's NK Cell Product* for designation as orphan medicinal product to the European Commission (EC).

*) Allogeneic ex vivo-generated natural killer cells from CD34+ umbilical cord blood progenitor cells for treatment of acute myeloid leukaemia

Subscribe to our newsletter

If you subscribe you agree to the Privacy Notice of Glycostem Therapeutics B.V. as found on the website.